Alnylam inks potential $93 million deal with Kyowa Hakko Kogyo

6/20/2008

CAMBRIDGE, Mass. Alnylam Pharmaceuticals has signed a collaborative deal with Kyowa Hakko Kogyo, that could be worth as much as $93 million, to develop and market the experimental respiratory drug ALN-RSV01, according to the Associated Press.

ALN-RSV01 is currently in midstage development for respiratory syncytial virus, which can cause severe lower respiratory infections, particularly in infants. Most of Alynlam's pipeline, though, is still in the preclinical phase of development, with potential candidates for liver cancer, Huntington's disease, pandemic flu, and cystic fibrosis, among others.

This is the company’s second recent deal. At the end of May, Alnylam signed a research partnership deal with Takeda Pharmaceuticals worth as much as $1 billion.

X
This ad will auto-close in 10 seconds